Evaluating the Efficacy and Safety of Co-administrated Rosuvastatin/Ezetimibe and Telmisartan
A Randomized, Double-blind, Active-controlled, Multicenter Phase3 Trial to Evaluate the Efficacy and Safety of Co-administrated Rosuvastatin/Ezetimibe and Telmisartan in Patients With Primary Hypercholesterolemia and Essential Hypertension
Sponsor: Addpharma Inc.
This PHASE3 trial investigates Hypercholesterolemia and Hypertension and is currently completed. Addpharma Inc. leads this study, which shows 6 recorded versions since 2019 — indicating limited longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.
Status Flow
Change History
6 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Feb 2021 — Jul 2024 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
-
Jan 2021 — Feb 2021 [monthly]
Active Not Recruiting PHASE3
▶ Show 1 earlier version
-
Apr 2019 — Jan 2021 [monthly]
Active Not Recruiting PHASE3
First recorded
Feb 2019
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Addpharma Inc.
For direct contact, visit the study record on ClinicalTrials.gov .